Westfield Capital Management Co. LP Purchases New Shares in Abivax SA Sponsored ADR $ABVX

Posted by on Jun 5th, 2026

Westfield Capital Management Co. LP purchased a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,009,966 shares of the company’s stock, valued at approximately $136,199,000. Westfield Capital Management Co. LP owned approximately 1.29% of Abivax as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. TCG Crossover Management LLC grew its stake in shares of Abivax by 17.4% in the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock valued at $603,774,000 after acquiring an additional 1,055,000 shares in the last quarter. UBS Group AG grew its stake in shares of Abivax by 2,561.0% in the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock valued at $378,761,000 after acquiring an additional 4,293,606 shares in the last quarter. Darwin Global Management Ltd. acquired a new position in shares of Abivax in the third quarter valued at about $263,698,000. Paradigm Biocapital Advisors LP acquired a new position in shares of Abivax in the third quarter valued at about $132,800,000. Finally, Octagon Capital Advisors LP grew its stake in shares of Abivax by 3.0% in the second quarter. Octagon Capital Advisors LP now owns 1,267,000 shares of the company’s stock valued at $9,693,000 after acquiring an additional 37,000 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Abivax Trading Up 16.4%

Shares of NASDAQ:ABVX opened at $104.93 on Friday. The firm has a 50 day moving average of $117.00 and a 200-day moving average of $119.83. The stock has a market capitalization of $8.36 billion, a PE ratio of -20.14 and a beta of 0.69. Abivax SA Sponsored ADR has a 12 month low of $5.69 and a 12 month high of $148.83.

Abivax (NASDAQ:ABVX – Get Free Report) last issued its earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.23. The firm had revenue of $1.56 million during the quarter, compared to analyst estimates of $0.40 million. On average, research analysts predict that Abivax SA Sponsored ADR will post -3.18 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ABVX has been the topic of several research reports. Oddo Bhf restated an “outperform” rating on shares of Abivax in a research note on Thursday, April 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research note on Monday, April 20th. Wolfe Research set a $136.00 target price on shares of Abivax in a research report on Wednesday. Citigroup restated an “outperform” rating on shares of Abivax in a research report on Tuesday. Finally, Barclays boosted their target price on shares of Abivax from $142.00 to $148.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. Twelve investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $130.08.

Check Out Our Latest Research Report on ABVX

Abivax Company Profile

(Free Report)

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.

Read More

Institutional Ownership by Quarter for Abivax (NASDAQ:ABVX)

Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.